Accessibility settings

This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (463) Health Services in Resource-Poor Settings and LMICs (585) Infectious Diseases (non-STD/STI) (1768) Outbreak and Pandemic Preparedness and Management (1855) COVID-19 Vaccination (190)

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/81323, first published .
Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial

Authors of this article:

George Peter Judicate1, 2 Author Orcid Image ;   Marco Missanga3 Author Orcid Image ;   Mbazi Senkoro1 Author Orcid Image ;   Emmanuel Kapesa3 Author Orcid Image ;   Nhamo Chiwerengo4 Author Orcid Image ;   Redemta Ferdinand1 Author Orcid Image ;   Gibson Kagaruki1 Author Orcid Image ;   Godfather Kimaro1 Author Orcid Image ;   Esther Ngadaya1 Author Orcid Image ;   Sokoine Lesikari Kivuyo1 Author Orcid Image ;   Deus Buma5 Author Orcid Image ;   Lwitiho Sudi3 Author Orcid Image ;   Abisai Kisinda3 Author Orcid Image ;   Lucas Maganga3 Author Orcid Image ;   Doreen Pamba3 Author Orcid Image ;   Joel Mwakisisile3 Author Orcid Image ;   Willyhelmina Olomi4 Author Orcid Image ;   Nyanda Ntinginya Elias3 Author Orcid Image ;   Said Aboud6 Author Orcid Image ;   Philemon Wambura7 Author Orcid Image ;   Sayoki Mfinanga1 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.